Lilly's move on oral protein delivery

It's been a long time coming, but it's beginning to look as if oral delivery of proteins will be technically feasible. The latest indicator is a $60 million deal by Eli Lilly and Co. to license Emisphere Technologies Inc.'s delivery technology, with a major focus in endocrinology, including growth disorders.

"The issues in oral delivery of proteins have been whether you can deliver proteins

Read the full 632 word article

How to gain access

Continue reading with a
two-week free trial.